Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug

Colleen Rivard, Melissa Geller, Erica Schnettler, Manju Saluja, Rachel Isaksson Vogel, Ashok Saluja, Sundaram Ramakrishnan

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Objective Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo.

Methods The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth.

Results Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice.

Conclusions Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.

Original languageEnglish (US)
Pages (from-to)318-324
Number of pages7
JournalGynecologic oncology
Issue number2
StatePublished - Nov 1 2014
Externally publishedYes


  • Chemotherapy
  • Minnelide
  • Ovarian cancer
  • Triptolide

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug'. Together they form a unique fingerprint.

Cite this